Patent applications published 17 February 2010
Patent applications taken from the weekly European Patents Bulletin
- Compsns of (-)-E-10-OH-NT and methods for the synthesis and use
Adolor 2152074*
- Methods and compsns for promoting localisation of pharmaceutically active agents to bone
Affinergy 2152075*
- Pulsatile dosing of gossypol for treatment of disease
Ascenta Therapeutics 2152076*
- Formulations containing clopidogrel and sulphoalkyl ether cyclodextrin and methods of use
CyDex Pharmaceuticals 2152078*
- Heterocyclic compounds and uses thereof
Avila Therapeutics 2152079*
- Novel soluble 1,4-benzodiazepine compounds and stable salts thereof
The Regents of the University of Michigan 2152080*
- Novel compounds
High Point Pharmaceuticals 2152081*
- Tetracyclic inhibitors of fatty acid amide hydrolase
The Scripps Research Institute 2152082*
- Method of manufacturing a ruthenium complex
Niki Pharma 2152084*
- Erythropoietin complementation or replacement
Normoxys 2152085*
- Methods and compsns for administration of oxybutynin
MicroDose Therapeutx 2152232*
- High concentration factor VII polypeptide formulations comprising an aromatic preservative and an antioxidant
Novo Nordisk Health Care 2152233*
- Lyophilised pharmaceutical compsns and methods of making and using same
Cephalon; Cephalon France 2152234*
- Aqueous aerosol preparations containing therapeutically active micro-organisms or parts of micro-organisms and method for producing corresponding aerosols
Boehringer Ingelheim International 2152235*
- Pharmaceutical compsn of an anthracycline
Nerviano Medical Services 2152236*
- Novel pharmaceutical compsn
SmithKline Beecham 2152237*
- Oronasopharyngeally deliverable pharmaceutical compsns of dopamine agonists for the prevention and/or treatment of restless limb disorders
Schwarz Pharma 2152238*
- Stable oxalaplatin compsn for parenteral administration
Intas Pharmaceuticals 2152239*
- Pharmaceutical compsns and methods for enhancing targeting of therapeutic compounds to the central nervous system
Healthpartners Research Foundation 2152240*
- Method of delivering a protein into a cell
Agency for Science, Technology and Research 2152241*
- Highly concentrated insulin solutions and compsns
Novo Nordisk 2152243*
- Oral delivery of proteins and peptides
Technion Research & Development Foundation 2152244*
- Method for drying a protein compsn, a dried protein compsn and a pharmaceutical compsn containing the dried protein
Novo Nordisk 2152245*
- Solid compsn comprising a clay such as kaolin
GlaxoSmithKline Consumer Healthcare 2142246*
- Anti-insomnia compsns and methods
Novadel Pharma 2152247*
- Controlled release tablet formulation containing magnesium aluminometasilicate
Jagotec 2152248*
- Oral dosage form providing fast absorption of drug
Novartis 2152249*
- Solid dosage forms comprising an enteric coating with accelerated drug release
Evonik Roehm 2152250*
- Increased drug loading capacity of polymeric material
Medtronic 2152251*
- Selective proteasome inhibitors for treating diabetes
The Trustees of Columbia University in the City of New York 2152252*
- Synergistic active preparations comprising 1,2-decanediol and further antimicrobial active compounds
Symrise 2152253*
- Reservatrol containing compsn for modulating bone formation
Uniaeo Brasileira De Educacao E Assistencia 2152254*
- Ophthalmic formulations of amyloid-contrast agents and methods of use thereof
Neuroptix 2152255*
- Telomerase activating compounds and methods of use thereof
Ben Gurion University of the Negev Research and Development Authority 2152256*
- Diabetic wound healing
CytRx 2152257*
- Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acrinide and uses thereof
Avalon Pharmaceuticals 2152258*
- Use of a naphtoic acid derivative in combination with red and/or blue light for treating acne vulgaris
Galderma Research & Development 2152259*
- An antibacterial formulation comprising a dialkyl sulphosuccinate and a carbanilide antibacterial agent
Synoptix 2152260*
- Treatment of virally induced lesions
Peplin Research 2152261*
- New heterocyclic derivatives useful for the treatment of CNS disorders
UCB Pharma 2152262*
- Compsns useful for treating gastrooesophageal reflux disease
Dynogen Pharmaceuticals 2152263*
- Antimicrobial formulations of a pyridine thiol and a bis-quinolinium salt
Synoptix Group 2152264*
- New method for preparing isofagomine and its derivatives
Amicus Therapeutics 2152265*
- Compsns and methods for treating disorders associated with salt or fluid retention
Ironwood Pharmaceuticals 2152266*
- Treatment of Imatinib resistant leukaemia using 4-aminoquinoline-3-carbonitriles
Wyeth 2152267*
- Method of treating diabetes
CV Therapeutics 2152268*
- Piperadine/piperazine derivatives
Janssen Pharmaceutica 2152269*
- Piperadine/piperazine derivatives
Janssen Pharmaceutica 2152270*
- Piperadine/piperazine derivatives
Janssen Pharmaceutica 2152271*
- Novel 2,3-diamino-quinazolinone derivatives and their medical use
NeuroSearch 2152272*
- Polymerase inhibitors and the use thereof for the treatment of tumours
Freie Universitaet Berlin; Heinrich-Heine-Universitaet Dusseldorf 2152273*
- Nasal administration of benzodiazepines
Questor Pharmaceuticals 2152274*
- Method of identifying genes involved in memory formation using small interfering RNA (SIRNA)
Helicon Therapeutics 2152275*
- Screening assay to identify correctors of protein trafficking defects
Traffick Therapeutics 2152276*
- Amido-amine dendrimer compsns
Genzyme 2152277*
- Enhancement of the calcium sensing receptor
Smith & Nephew 2152278*
- Use of biological surfactant as anti--inflammatory agent and tissue preservation solution
Seoul National University Industry Foundation 2152279*
- Branched-chain amino acid compsn for improving skeletal muscle protein metabolism
Northern Innovations and Formulations 2152280*
- Compsn for the treatment of ischaemic heart disease, facilitation of blood circulation and angiogenesis, improving skin beauty, improving male sexual function containing genseng berry extract
Amorepaccfi 2152281*
- Method and preparation of herbal extract of calotropis gigantea for cancer treatment
Zacharia, Jacob 2152282*
- Water soluble opuntia extracts for the inhibition of alpha-1-adrenergic receptors
Naturamed 2152283*
- Compsn for maintaining androgen and androgen-like uptake potential by cells
Northern Innovations and Formulations 2152285*
- Herbal formulation for treatment of depression and other related disorders and method of preparing the same
Vita Green Health Products 2152286*
- Methods for treating and preventing GI syndrome and graft versus host disease
Sloan Kettering Institute for Cancer Research 2152287*
- Reconstituted surfactants having improved properties
Chiesi Farmaceutici 2152288*
- Novel antimicrobial agents
Technion Research & Development Foundation 2152289*
- Method for administering anti-IL-5 antibodies
SmithKline Beecham 2152290*
- Use of cyclosporines in the treatment of patients with intraocular lenses
Allergan 2152291*
- Angiogenesis inhibitor comprising meteorin as an active ingredient
SNU R&DB Foundation 2152292*
- Compsns for protein delivery and methods of use thereof
The Board of Regents of the University of Nebraska 2152293*
- Methods of modulating homeostatic pathways and cellular survival
Dana-Farber Cancer Institute 2152294*
- Klotho protein and related compounds for the treatment and diagnosis of cancer
Tel HaShomer Medical Research Infrastructure and Services; Cedars-Sinai Medical Centre 2152295*
- Injectable ready to use solutions comprising human chorionic gonadotropin
Dong-a-Pharm 2152296*
- Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
Alize Pharma 2152297*
- Modified nucleotide sequence encoding glucagon-like peptide-1 (GLP-1)
Boehringer Ingelheim International 2152298*
- Pharmaceutical and/or cosmetic compsn containing aconitase-activating active ingredients
Societe d"Extraction des Principes Actifs 2152299*
- Functional humanisation of complementarity determining regions
Sinomab Bioscience 2152300*
- Trypanosoma antigens, vaccine compsns and related methods
Fraunhofer USA 2152301*
- Formulation of meningitis vaccines
Novartis 2152302*
- Chlamydial antigens as reagents for diagnosis and treatment of chalmydial infection and disease
Board of Regents, The University of Texas System 2152303*
- Nanoemulsion therapeutic compsns and methods of using the same
The Regents of the University of Michigan 2152304*
- Immediate protection against pathogens via MVA
Bavarian Nordic 2152305*
- PRRSV vaccines based on GP5 proteins
MJ Biologics 2152306*
- Inhibition of tumour metastasis by anti-neuropilin 2 antibodies
Genentech 2152307*
- New indications for anti IL-1-Beta therapy
Novartis 2152308*
- Methods and device to neutralise soluble toxic agents in the brain
Medtronic 2152309*
- Methods for administering anti-IL-5 antibodies
SmithKline Beecham 2152310*
- Set of means for treating a malignant pathology, an autoimmune disease or an infectious disease
LFB Biotechnologies 2152311*
- Low-viscous anthracycline formulation
KTB Tumorforschungs-gesellschaft 2152312*
- Oral nicotine formulation buffered with amino acid
McNeil 2152313*